These findings align with established models linking IL-6 dysregulation to metabolically induced fibrogenic signaling, reinforcing its central role in defining the inflammation-dominant profile of ATD-driven MASLD [14,26]. The gene discussed is IL6; the disease is Jeune syndrome.